<DOC>
	<DOCNO>NCT01103596</DOCNO>
	<brief_summary>The purpose study evaluate , patient least second protease inhibitor ( PI ) line , virological failure Kaletra® consequence protease reverse transcriptase genotype</brief_summary>
	<brief_title>Evaluation Public Health Interest Kaletra : Impact Resistance Antiretrovirals ( ARVs )</brief_title>
	<detailed_description>The purpose study evaluate , patient least second PI line , virological failure Kaletra® consequence protease reverse transcriptase genotype : - Characterisation change resistance genotype protease reverse transcriptase , - Description nature frequency select mutation Kaletra® , - Description predictive factor mutation impact could PIs use maintenance treatment ( analysis base available algorithm ) . EOLE prospective , multicentre observation study offer French virology laboratory involve clinical team . It transversal study retrospective data collection patient meeting study criterion ( virological failure Kaletra® least first line PI treatment ) . The study comprise two enrolment period , separate interval one year , period range 2007 2011 . During period , virological failure Kaletra® identify . For period , virologist collect data moment virological failure Kaletra® identify . The first wave data collection complete occur December 5 , 2007 July 03 , 2009 . It plan collect follow-up data connection alternative treatment antiretrovirals failure Kaletra® .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patient age 18 year , Pretreated least one protease inhibitor ( PI ) line , In therapeutic failure antiretroviral ( ARV ) maintenance treatment contain Kaletra® . Therapeutic failure define viral load &gt; 50 copies/ml least three month ' treatment ARV combination contain Kaletra® , always provide genotyping possible . Patients receive less three month Kaletra® , Patients genotype information start Kaletra® time failure Kaletra® available , Patients receive another protease inhibitor ( PI ) concomitantly Kaletra® .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Evaluation impact Kaletra antiretroviral resistance</keyword>
</DOC>